Cancer drug imatinib tested for rare eye melanoma – but trial stops early

NCT ID NCT00421317

Terminated Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested the drug imatinib in 13 adults with metastatic ocular melanoma, a rare eye cancer that has spread. The goal was to see if imatinib could stop tumor growth for at least 3 months. The trial was terminated early, so the results are limited and it is unclear if imatinib helps patients with this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imatinib
What this could lead to: If it works, this could point toward a treatment option for metastatic ocular melanoma, a rare and hard-to-treat cancer.
What could go wrong: This trial was terminated early and enrolled only 13 people, so results are very limited. Imatinib may not shrink tumors or improve survival, and it can cause side effects like fatigue, nausea, and liver problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma ocular melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Centre Francois Baclesse

Caen, 14076, France
Centre Georges-Francois Leclerc

Dijon, 21079, France
Centre Gustave Roussy

Villejuif, 94805, France
Centre Hospitalier Regional Universitaire

Lille, 59035, France
Centre Jean Perrin

Clermont-Ferrand, 63011, France
Centre Leon Berard

Lyon, 69373, France
Centre Oscar Lambret

Lille, 59020, France
Centre Paul Strauss

Strasbourg, 67065, France
Centre Val d'Aurelle Paul Lamarque

Montpellier, 34298, France
Hopital Universitaire de Hautepierre

Strasbourg, 67098, France
Institut Claudius Regaud

Toulouse, 31052, France
Institut Curie

Paris, 75248, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.